2025-05-19-Jefferies-吉利德科学（GILD）_暴露前预防（PrEP）调查显示如果Len药物很快获批_患者似乎看好改用该药物_44页_1mb
报告摘要
- Equity Research Summary on Gilead Sciences (GILD)
- Focus: Analysis of Gilead Sciences' long-acting PrEP drug, lenacapavir, with a PDUFA approval date of June 19, 2025.
- Key Findings: A survey of ~560 patients shows high awareness (~70% aware despite non-approval) and strong preference for switching (~95% of current PrEP users would swap, primarily from generic Truvada and Descovy). This positions lenacapavir to capture significant market share, with 50% of uninitiated patients expressing interest, suggesting market expansion potential up to 1M users by mid-2030. Current PrEP market is $400K, growing ~15% YY, with opportunities from under-utilization and increased awareness.
- Financial Analysis: Jefferies maintains a Buy rating with a $130 price target, based on DCF models projecting $4-8B+ revenue potential post-launch. Scenarios assume 25-90% swap from Descovy and Truvada, with EPS estimates leading to 12-14x multiples. Current stock trades at $102.50, undervalued at 12.5x FY2025 EPS, with upside if launched successfully in 2026.
- Catalysts: Approval window closing June 19, management-FDA dialog positive, and projected 75-90% access expansion within months. Positive commentary emphasizes swap potential from oral pills due to convenience and compliance benefits.
- Risks: Near-term uncertainty around FDA approval, competition from generics, pricing pressures, and potential delays in access or reimbursement. Pipeline risks include competitor actions and market reception of long-acting therapies.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
